GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vcanbio Cell & Gene Engineering Corp 600645.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

17.30

-1.42%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥1.45bn

FY2016FY2025

Net income

CN¥113.8m

FY2016FY2025

Free cash flow

CN¥264.1m

FY2016FY2025

Shareholders' equity

CN¥3.71bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥1.45bnCN¥1.59bnCN¥1.59bnCN¥1.55bnCN¥1.54bnCN¥1.32bnCN¥1.39bnCN¥1.32bnCN¥1.32bnCN¥837.9m
Gross profitCN¥1.02bnCN¥1.09bnCN¥1.08bnCN¥1.04bnCN¥1.06bnCN¥867.8mCN¥935.5mCN¥866.3mCN¥879.0mCN¥543.0m
Research and developmentCN¥149.0mCN¥182.1mCN¥184.5mCN¥147.3mCN¥135.3mCN¥114.4mCN¥109.6mCN¥103.3mCN¥104.3mCN¥46.9m
Operating incomeCN¥196.5mCN¥135.8mCN¥131.1mCN¥156.0mCN¥219.8m−CN¥92.7mCN¥114.8mCN¥44.2mCN¥62.7mCN¥84.0m
Net incomeCN¥113.8mCN¥100.4mCN¥106.5mCN¥113.0mCN¥155.3m−CN¥126.9mCN¥49.7mCN¥59.3mCN¥10.4mCN¥37.9m
Diluted earnings per share0.250.220.230.240.32-0.270.110.150.030.11

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥5.29bnCN¥5.25bnCN¥5.41bnCN¥5.28bnCN¥5.03bnCN¥4.88bnCN¥4.89bnCN¥4.44bnCN¥3.00bnCN¥3.00bn
Cash and short-term investments—CN¥1.52bnCN¥1.58bnCN¥1.39bnCN¥1.20bnCN¥1.06bnCN¥1.03bnCN¥585.2mCN¥252.5mCN¥413.5m
Total liabilitiesCN¥1.54bnCN¥1.59bnCN¥1.61bnCN¥1.63bnCN¥1.50bnCN¥1.38bnCN¥1.43bnCN¥1.46bnCN¥1.37bnCN¥1.25bn
Debt—CN¥68.4mCN¥115.9mCN¥129.6mCN¥87.3mCN¥110.5mCN¥135.5mCN¥195.1mCN¥178.9mCN¥117.8m
Shareholders' equityCN¥3.71bnCN¥3.60bnCN¥3.68bnCN¥3.56bnCN¥3.46bnCN¥3.42bnCN¥3.35bnCN¥2.77bnCN¥1.51bnCN¥1.59bn
Shares outstanding456m462m468m468m486m471m434m389m363m349m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥313.6mCN¥285.2mCN¥299.0mCN¥261.9mCN¥321.0mCN¥244.4mCN¥241.5mCN¥130.1mCN¥70.3mCN¥143.7m
Capital spending−CN¥49.6m−CN¥67.3m−CN¥88.6m−CN¥99.2m−CN¥127.7m−CN¥91.7m−CN¥123.0m−CN¥128.1m−CN¥83.0m−CN¥269.8m
Free cash flowCN¥264.1mCN¥217.9mCN¥210.4mCN¥162.7mCN¥193.2mCN¥152.6mCN¥118.5mCN¥1.9m−CN¥12.7m−CN¥126.2m
Dividends paid—−CN¥591,243−CN¥917,346−CN¥1.3m−CN¥1.6m−CN¥4.0m−CN¥11.3m−CN¥11.7m−CN¥11.6m−CN¥8.5m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥342.0mCN¥317.3mCN¥362.5mCN¥376.1mCN¥365.6mCN¥350.8mCN¥379.5mCN¥403.6m
Gross profitCN¥247.1mCN¥220.8mCN¥260.0mCN¥264.1mCN¥245.8mCN¥239.6mCN¥245.7mCN¥289.8m
Operating incomeCN¥43.8mCN¥35.4mCN¥51.8mCN¥57.6mCN¥39.0mCN¥36.4m−CN¥41.2mCN¥62.4m
Net incomeCN¥36.8mCN¥24.2mCN¥5.9mCN¥50.1mCN¥29.7mCN¥28.0m−CN¥33.2mCN¥48.3m
Diluted earnings per share0.080.050.010.110.070.06-0.070.10
Cash from operations———CN¥103.0mCN¥76.0mCN¥46.0mCN¥107.0mCN¥78.0m
Capital spending−CN¥10.0m−CN¥8.0m−CN¥12.0m−CN¥13.0m−CN¥12.0m−CN¥10.0m−CN¥14.0m−CN¥11.0m
Free cash flow———CN¥90.0mCN¥64.0mCN¥36.0mCN¥93.0mCN¥67.0m
Total assetsCN¥5.29bnCN¥5.27bnCN¥5.29bnCN¥5.32bnCN¥5.25bnCN¥5.25bnCN¥5.25bnCN¥5.28bn
Cash and short-term investments———CN¥1.66bnCN¥1.60bnCN¥1.55bnCN¥1.52bnCN¥1.44bn
Debt———CN¥21.1mCN¥38.3mCN¥42.3mCN¥43.8mCN¥40.8m
Shareholders' equityCN¥3.74bnCN¥3.72bnCN¥3.71bnCN¥3.71bnCN¥3.65bnCN¥3.62bnCN¥3.60bnCN¥3.62bn

Financial ratios

Data as of 3 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin69.8%68.6%68.2%67.2%69.1%65.8%—
Operating margin13.5%8.6%8.2%10.0%14.3%-7.0%—
Net margin7.8%6.3%6.7%7.3%10.1%-9.6%—
Return on equity3.1%2.8%2.9%3.2%4.5%-3.7%—
Return on assets2.2%1.9%2.0%2.1%3.1%-2.6%—
Free cash flow yield4.1%3.9%4.3%4.0%4.8%3.7%—
Revenue growth-8.2%-0.3%2.2%1.3%16.4%-4.9%—
Earnings growth13.4%-5.7%-5.8%-27.3%-222.4%-355.3%—
Current ratio1.82x1.65x1.69x1.57x1.45x1.45x—
Debt to equity—0.01x0.01x0.01x0.02x0.02x0.01x
Equity ratio70.0%68.5%68.1%67.3%68.8%70.0%—
Interest coverage—26.97x11986.89x66.53x114.76x-50.16x10.54x
R&D as a share of sales10.2%11.5%11.6%9.5%8.8%8.7%—
Buybacks as a share of market value1.2%1.3%0.0%3.8%-3.3%-8.5%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.2%2.0%7.5%
Operating income8.0%—-2.5%
Net income0.2%—-5.9%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin69.2%68.4%68.2%67.4%
Operating margin10.9%10.0%8.3%8.9%
Net margin7.0%7.0%5.1%5.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings101.088.889.170.579.0-72.8147.8106.5—246.9
Price to sales7.95.66.05.18.07.05.34.87.811.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 10 Aug 2001.

FY2001FY1998FY1995
Paid in the year0.0080.0480.093
  • 13-for-10 split · 25 Jan 2007
  • 8-for-5 split · 10 Aug 2001
  • 13-for-10 split · 12 May 1997
  • 6-for-5 split · 24 Jun 1996
  • 3-for-2 split · 25 Apr 1994
  • 1.895-for-1 split · 23 Aug 1993

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.